Published in final edited form as:

Oral Oncol. 2014 March ; 50(3): 196–199. doi:10.1016/j.oraloncology.2013.11.007.

***RAD51C* – a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC)**

Kathrin Scheckenbach^{1,*}, Stephan E. Baldus², Vera Balz¹, Marcel Freund¹, Petra Pakropa¹, Christoph Sproll³, Karl-Ludwig Schäfer², Martin Wagenmann¹, Jörg Schipper¹, and Helmut Hanenberg^{1,4,5}

¹Department of Otorhinolaryngology, Head and Neck Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany

²Department of Pathology, Heinrich Heine University, 40225 Düsseldorf, Germany

³Department of Cranio-and-Maxillo Facial Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany

⁴Pediatric Hematology/Oncology, Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, U.S.A

⁵Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, U.S.A

Abstract

Introduction—Head and neck squamous cell carcinomas (HNSCCs) are one of the leading causes of cancer-associated death worldwide. Although certain behavioral risk factors are well recognized as tumor promoting, there is very little known about the presence of predisposing germline mutations in HNSCC patients.

Methods—In this study, we analyzed 121 individuals with HNSCCs collected at our institution for germline alterations in the newly identified cancer susceptibility gene *RAD51C*.

Results—Sequencing of all exons and the adjacent introns revealed five distinct heterozygous sequence deviations in *RAD51C* in seven patients (5.8%). A female patient without any other risk factors carried a germline mutation that disrupted the canonical splice acceptor site of exon 5 (c. 706-2A>G).

Conclusions—As there are only a few publications in the literature identifying germline mutations in head and neck cancer patients, our results provide the first indication that paralogs of *RAD51*, recently implemented in breast and ovarian cancers, might also be candidates for genetic risk factors in sporadic squamous cell carcinomas of the head and neck.

*Corresponding authors: Kathrin Scheckenbach, MD, scheckenbach@med.uni-duesseldorf.de, Department of Otorhinolaryngology, Head and Neck Surgery, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany, Tel: 211-811-7571; Fax: 211-811-8880.

Conflict of interest statement

Kathrin Scheckenbach, Marcel Freund and Helmut Hanenberg may receive royalties based on a licensing agreement with Myriad Genetics for the use of *RAD51C* as a cancer susceptibility gene. All other authors declare to have no conflict of interest.

Introduction

Six percent of all human malignant tumors worldwide are squamous cell carcinomas of the head and neck region (HNSCCs) (1). In Europe, the consumption of alcohol and nicotine are the main behavioral risk factors to develop HNSCC (2, 3), however infections with the oncogenic human papilloma virus (HPV) –16 or –18 strains also contribute significantly to tumorigenesis and incidence of HNSCCs (4). Genetic factors might also play a role in the development of HNSCCs at a relatively early age and especially in the absence of any known tumorigenic trigger, however almost all changes described were somatic mutations present in the tumor cells (5–13).

Fanconi anemia (FA) is a rare inherited recessive disorder usually diagnosed around 10 years of age, where patients without behavioral risk factors frequently develop HNSCCs in their early adulthood (14–17). The genetic causes for FA are autosomal or X-chromosomal germline defects in at least 16 different genes involved in the repair of DNA crosslinks at stalled replication forks (18–22). Cells with defects in the FA pathway show spontaneous chromosomal instability and a characteristic hypersensitivity to DNA crosslinking agents such as mitomycin C (MMC) (23). Clinically, FA patients are characterized by congenital abnormalities, progressive bone marrow failure, and the predisposition to leukemia and epithelial cancers (15). Remarkably, about 50% of FA patients without stem cell transplantation and nearly 100% of transplanted FA patients develop a squamous cell carcinoma of the head and neck until 45 years of age (17).

During the last six years, heterozygous germline and also acquired defects of FA genes were identified in patients with sporadic epithelial cancers such as breast (24–26), ovarian (27, 28), cervical (29), lung (30), pancreatic (31, 32) or testicular cancer (33). Since genetic instability is also seen as a major force for driving head and neck cancer tumorigenesis (34), heterozygous germline defects in genes of the FA pathway could also be a predisposing genetic condition for the development of HNSCC. Indeed, initial work identified defects in the FA pathway in sporadic HNSCCs, such as downregulation of several FA genes in sporadic HNSCCs (35), inactivating promoter methylation in *FANCB* (36) and defective FANCD2 foci formation after stimulation (37).

Recently, we identified *RAD51C* (*RAD51L2*), putatively designated as *FANCO* (38), as a human cancer susceptibility gene for inherited breast and ovarian malignancies (39). *RAD51C* is one of five paralogues (*RAD51B*, *RAD51C*, *RAD51D*, *XRCC2*, *XRCC3*) of the highly conserved *RAD51* recombinase that plays a central role in the homologous repair (HR) of DNA double strand breaks (DSBs) in mammalian cells, mediating homologous DNA pairing and strand exchange (40, 41). In cells that are defective in any of the paralogues, the formation of *RAD51* foci is strongly reduced in response to DNA damage and correlates with decreased HR efficiency, increased genomic instability and a higher incidence of chromosomal abnormalities (41, 42).

In order to determine whether *RAD51C* germline mutations are also a predisposing condition for the development of HNSCC, peripheral blood (PB) DNA from 121 patients

(male: 97; 80.2%, female: 24; 19.8%) diagnosed with sporadic HNSCCs at our institution was analyzed for *RAD51C* mutations by direct sequencing (38, 39).

Materials and Methods

Patients

PB samples were collected from 121 consecutive patients of the Department of Otorhinolaryngology (Heinrich-Heine University, Düsseldorf, Germany) with histologically confirmed HNSCCs, including all sites (55 oropharynx, 20 hypopharynx, 27 larynx, 7 Sinus, 2 scalp, 10 CUP (carcinoma of unknown primary)) and stages (cis, T₁₋₄, N₀₋₃, M_{0/1}) of disease after obtaining informed consent. Research was carried out in compliance with the Helsinki Declaration. This study was reviewed and approved by the ethics committee of the University of Düsseldorf (Study No. 3515).

HPV Status

For immunohistochemical staining of p16/INK4a, 2-µm sections were stained using the CINtec PLUS kit (mtm Laboratories, Heidelberg, Germany) according to the manufacturer's instructions as described previously (43).

Sequencing of all 9 exons of the *RAD51C* gene

DNA was isolated from PB leukocytes according to the manufacturer's recommendation (Genomic DNA purification kit, Gentra Biosystems, Minneapolis, USA). Each of the 9 exons of the *RAD51C* gene was amplified in a standard PCR reaction using Qiagen Mastermix (Qiagen, Hilden, Germany). Primers and PCR conditions are shown in Table 1. The PCR products were purified (Qiaquick PCR Purification Kit, Qiagen), and mixed with ABI PRISM BigDye Terminator sequencing kit (Applied Biosystems, Weiterstadt, Germany) and primers for sense direction or for antisense direction (Table 1). After the sequencing reaction (25 cycles of 15 sec at 96°C and 4 min at 60°C), the products were purified (DyeEx 2.0 Spin Kit, Qiagen) and analyzed with an automated sequencer (ABI 310, Applied Biosystems). Positive samples underwent confirmation by repeated analysis.

Results

In total, we identified five heterozygous germline alterations in seven (3 females, 4 males) out of 121 individuals. All sequence changes were single nucleotide alterations (Table 2). The mutation c.706-2A>G was located in the canonical splice acceptor dinucleotide of intron 4 in the germline DNA from a female without any behavioral risk factors and is clearly pathogenic as it leads to a loss of exon 5 in the mRNA resulting in an in-frame deletion of 44 amino acids, pV236del44, in the *RAD51C* protein. This germline mutation was previously described by Walsh *et al.* 2011 (44) in a 70-year old stage IV ovarian cancer patient with loss-of-heterozygosity (LOH) in the tumor tissue and by Loveday *et al.* 2012 (45) in a 56-year old female with ovarian cancer. Four missense alterations identified in six patients were located in the exons 1 (1×, c.7G>A, p.G3R), 2 (2×, c.376G>A, p.A126T), 5 (1×, c.790G>A, p.G264S) and 6 (2×, c.859A>G, p.287A), respectively.

Four of the HNSCCs were located at the larynx, two in the oropharynx and one in the hypopharynx. The two patients with laryngeal carcinomas developed additional malignancies: one experienced an oropharyngeal carcinoma and one was diagnosed with bronchial carcinoma (Table 2). As overexpression of the p16 protein can be used as a surrogate marker for HPV infection in tissues (45), we analyzed the available tumor tissue samples of the seven patients by immunohistochemistry: samples from three patients stained p16 positive, suggesting HPV infections, and three samples were negative. From one patient (#5), tumor tissue was not available. Two patients had a combined history of regular alcohol uptake and cigarettes consumption, two other individuals smoke cigarettes, while three patients were not exposed to any of these drugs (Table 2).

Discussion

We identified five *RAD51C* germline alterations in seven patients with sporadic HNSCC, representing 5.8% of all analyzed 121 individuals. All patients who carried *RAD51C* alterations had tumors that originate from the mucus membrane as most frequent carcinoma type in our series. Four of the five changes were missense alterations that we previously reported in individuals from German pedigrees with breast and ovarian cancers (39). The functional characterizations of these four *RAD51C* alterations in this earlier study revealed that expression of c.7G>A (patient 1) and c.376G>A (patients 2 and 3) mutated *RAD51C* cDNAs transferred via retroviral vectors in *Rad51c*^{-/-} chicken DT40 cells and in human *RAD51C*-mutated fibroblasts was associated with normal cellular survival and normal *RAD51* foci formation in response to MMC exposure, respectively (39). In contrast, expression of the c.790G>A (patient 5) and the c.859A>G (patient 6 and 7) *RAD51C* alterations showed clearly reduced survival of *RAD51c*^{-/-} DT40 cells upon MMC challenge albeit normal *RAD51* foci formation (39). As the latter two missense alterations were associated with impaired cellular viability in response to DNA cross-linking agent MMC (39), we had hypothesized that these two alterations should therefore be associated with an increased cancer risk. However, comparative analysis with 2912 representative control individuals of the German population revealed that only the c.790G>A alteration in *RAD51C* was associated with an increased risk of 3.44 (confidence interval 1.51–7.8, $p < 0.005$) for developing gynecological cancers (39). A similar association of *RAD51C* c.790G>A mutation with an increased cancer risk was also confirmed in the British study by Loveday *et al.* (45). The fifth *RAD51C* germline alteration in our patient population was a splice acceptor mutation, c.706-2A>G, that disrupts the canonical AG splice acceptor site and thereby leads to a loss of exon 5 in the transcript and a frameshift in the open reading frame with premature protein truncation. This mutation was previously detected in two individuals with ovarian cancer and classified in both publications as detrimental (44, 45).

Strikingly, three out of the seven HNSCC patients with germline alterations in *RAD51C* were females (43%), while only 20% of all patients in our patient cohort were women. All three women did not have any history of tobacco and alcohol consumption as typical triggers for the development of HNSCCs. The tumor in the patient 3 with the functionally normal c.376G>A alteration (39) was classified as HPV positive, thus providing an explanation for the HNSCC development in this individual. Importantly, the absence of any risk factor in patient 4 (c.706-2A>G) with a HPV16/18 negative tumor and the development

of an independent lung cancer in patient 5 (c.790G>A) strongly indicated an underlying genetic cancer susceptibility in these two women, likely due to the *RAD51C* germline mutations. In contrast, all four male patients had a history of smoking cigarettes. Two also consumed alcohol and their tumors were classified as HPV positive. Therefore, the risk factor profiles in these four individuals were similar to those of patients without any alterations in *RAD51C* and characteristic for HNSCC patients. Hence, an association of the development of HNSCCs with germline changes in *RAD51C* was not evident in the four male patients.

The most important risk factors for HNSCCs in the western hemisphere are behavioral factors, predominantly chronic exposure to tobacco and/or alcohol and infection with HPV (4). HNSCC cancer carcinogenesis has been linked to abnormalities in DNA repair, apoptosis, carcinogen metabolism and cell cycle control (1) and somatic changes in associated genes in HNSCC tissues were described by several groups (5, 7, 8, 47–49). However, specific germline mutations predisposing to HNSCCs have only been identified in *P53* and *INK4a/p16* that are associated with a wide variety of human cancers (50, 51). Here, we provide first evidence that germline alterations in the established cancer susceptibility gene *RAD51C* (38, 39, 44, 45) are also present in HNSCC patients. These alterations in the *RAD51C* protein in at least 4 out of 121 patients (3%) are associated with reduced (patients 5, 6 and 7) (39) or absent (patient 4, c.706-2A>G) function, thus suggesting that germline mutations in genes of the FA pathway could contribute to the development of HNSCCs. Here, further studies of analyzing HNSCC patients for germline mutations in FA-associated genes will provide further insights whether the 'common disease, rare allele' hypothesis (52) might also apply to a subset of HNSCC patients at relatively young age and without known risk factors.

Acknowledgments

We would like to thank the patients for their help and support of the study. We are indebted to Peter Enczmann for using the capillary sequencer at the Institute for Transplantation Diagnostic and Cell Therapeutics, Heinrich Heine University.

This work is supported by the HHU Forschungsförderungsfond (to K.S.), the BMBF networks of inherited bone marrow failure syndromes (to H.H.) and Foamyvirus-mediated Genetic Therapy for *FANCA* (FoneFA, to H.H.) and the NIH R01s CA138237-01 and CA155294-01 (to H.H.). Helmut Hanenberg is supported by the Lilly Foundation Physician/Scientist initiative.

Literature

1. Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. *Eur Arch Otorhinolaryngol.* 2003; 260(9):502–508. [PubMed: 12736744]
2. Mashberg A, Boffetta P, Winkelmann R, Garfinkel L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. *Cancer.* 1993; 72(4):1369–1375. [PubMed: 8339227]
3. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res.* 1988; 48(11):3282–3287. [PubMed: 3365707]
4. Goon PK, Stanley MA, Ebmeyer J, et al. HPV & head and neck cancer: a descriptive update. *Head Neck Oncol.* 2009; 1(1):36. [PubMed: 19828033]

5. Lang JC, Borchers J, Danahey D, et al. Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF. *Int J Oncol.* 2002; 21(2):401–408. [PubMed: 12118338]
6. Yu KK, Zanation AM, Moss JR, Yarbrough WG. Familial head and neck cancer: molecular analysis of a new clinical entity. *Laryngoscope.* 2002; 112(9):1587–1593. [PubMed: 12352668]
7. Shao X, Tandon R, Samara G, et al. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. *Int J Cancer.* 1998; 77(5):684–688. [PubMed: 9688299]
8. Pai SI, Wu GS, Ozoren N, et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. *Cancer Res.* 1998; 58(16):3513–3518. [PubMed: 9721851]
9. Schwentner I, Witsch-Baumgartner M, Sprinzl GM, et al. Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. *Head Neck.* 2008; 30(8):1040–1044. [PubMed: 18528899]
10. Mahjabeen I, Baig RM, Masood N, et al. Genetic variations in XRCC1 gene in sporadic head and neck cancer (HNC) patients. *Pathol Oncol Res.* 2013; 19(2):183–188. [PubMed: 23055018]
11. Mahjabeen I, Baig RM, Sabir M, Kayani MA. Genetic and expressional variations of APEX1 are associated with increased risk of head and neck cancer. *Mutagenesis.* 2013; 28(2):213–218. [PubMed: 23408843]
12. Sabir M, Baig RM, Mahjabeen I, Kayani MA. Novel germline CDK4 mutations in patients with head and neck cancer. *Hereditary cancer in clinical practice.* 2012; 10(1):11. [PubMed: 22932448]
13. Sabir M, Baig RM, Mahjabeen I, Saeed M, Malik FA, Kayani MA. Rb1/105 gene alterations and head and neck carcinogenesis. *Molecular biology reports.* 2012; 39(10):9573–9581. [PubMed: 22744425]
14. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. *Arch Otolaryngol Head Neck Surg.* 2003; 129(1):106–112. [PubMed: 12525204]
15. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). *Blood.* 2003; 101(4):1249–1256. [PubMed: 12393516]
16. Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. *J Natl Cancer Inst.* 2003; 95(22):1718–1721. [PubMed: 14625263]
17. Rosenberg PS, Socie G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. *Blood.* 2005; 105(1):67–73. [PubMed: 15331448]
18. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. *N Engl J Med.* 2010; 362(20):1909–1919. [PubMed: 20484397]
19. Kitao H, Takata M. Fanconi anemia: a disorder defective in the DNA damage response. *International journal of hematology.* 2011; 93(4):417–424. [PubMed: 21331524]
20. Cybulski KE, Howlett NG. FANCP/SLX4: a Swiss army knife of DNA interstrand crosslink repair. *Cell Cycle.* 2011; 10(11):1757–1763. [PubMed: 21527828]
21. Kottmann MC, Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. *Nature.* 2013; 493(7432):356–363. [PubMed: 23325218]
22. Bogliolo M, Schuster B, Stoepker C, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. *Am J Hum Genet.* 2013; 92(5):800–806. [PubMed: 23623386]
23. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. *Mutation research.* 2009; 668(1–2):11–19. [PubMed: 19061902]
24. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet.* 2006; 38(11):1239–1241. [PubMed: 17033622]
25. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet.* 2007; 39(2):165–167. [PubMed: 17200668]
26. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. *Annu Rev Genomics Hum Genet.* 2008; 9:321–345. [PubMed: 18544032]

27. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. *Cancer Res.* 2002; 62(14):4151–4156. [PubMed: 12124354]
28. Taniguchi T, Tischkowitz M, Ameiziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. *Nat Med.* 2003; 9(5):568–574. [PubMed: 12692539]
29. Narayan G, Arias-Pulido H, Nandula SV, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. *Cancer Res.* 2004; 64(9):2994–2997. [PubMed: 15126331]
30. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. *Oncogene.* 2004; 23(4):1000–1004. [PubMed: 14647419]
31. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science.* 2009; 324(5924):217. [PubMed: 19264984]
32. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. *Cancer Res.* 2003; 63(10):2585–2588. [PubMed: 12750283]
33. Koul S, McKiernan JM, Narayan G, et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. *Mol Cancer.* 2004; 3:16. [PubMed: 15149548]
34. Friedlander PL. Genomic instability in head and neck cancer patients. *Head Neck.* 2001; 23(8):683–691. [PubMed: 11443752]
35. Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. *ORL J Otorhinolaryngol Relat Spec.* 2007; 69(4):218–225. [PubMed: 17409780]
36. Smith IM, Mithani SK, Mydlarz WK, Chang SS, Califano JA. Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers. *ORL J Otorhinolaryngol Relat Spec.* 2010; 72(1):44–50. [PubMed: 20332657]
37. Burkitt K, Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. *Cancer Lett.* 2007; 253(1):131–137. [PubMed: 17321670]
38. Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. *Nat Genet.* 2010; 42(5):406–409. [PubMed: 20400963]
39. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. *Nat Genet.* 2010; 42(5):410–414. [PubMed: 20400964]
40. Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. *Cell.* 1996; 87(4):757–766. [PubMed: 8929543]
41. Thacker J. The RAD51 gene family, genetic instability and cancer. *Cancer Lett.* 2005; 219(2):125–135. [PubMed: 15723711]
42. Takata M, Sasaki MS, Tachiiri S, et al. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. *Mol Cell Biol.* 2001; 21(8):2858–2866. [PubMed: 11283264]
43. Reuschenbach M, Roos J, Panayotopoulos D, Baldus SE, et al. Characterization of squamous cell cancers of the vulvar anterior fourchette by human papillomavirus, p16INK4a, p53. *J Low Genit Tract Dis.* 2013; 17(3):289–289. [PubMed: 23645067]
44. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A.* 2011; 108(44):18032–18037. [PubMed: 22006311]
45. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat Genet.* 2012; 44(5):475–476. author reply 6. [PubMed: 22538716]
46. Melkane AE, Mirghani H, Auperin A, et al. HPV-related oropharyngeal squamous cell carcinomas: A comparison between three diagnostic approaches. *Am J Otolaryngol.* 2013 (in press).

47. Sanchez-Cespedes M, Okami K, Cairns P, Sidransky D. Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. *Genes Chromosomes Cancer*. 2000; 27(3):319–322. [PubMed: 10679922]
48. Jefferies S, Edwards SM, Hamoudi RA, et al. No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours. *Br J Cancer*. 2001; 85(9):1383–1386. [PubMed: 11720478]
49. Poetsch M, Lorenz G, Kleist B. Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. *Cancer Genet Cytogenet*. 2002; 132(1): 20–24. [PubMed: 11801303]
50. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. *Semin Oncol*. 2002; 29(3):246–257. [PubMed: 12063677]
51. Vinarsky V, Fine RL, Assaad A, et al. Head and neck squamous cell carcinoma in FAMMM syndrome. *Head Neck*. 2009; 31(11):1524–1527. [PubMed: 19360740]
52. Walsh T, King MC. Ten genes for inherited breast cancer. *Cancer Cell*. 2007; 11(2):103–105. [PubMed: 17292821]

Table 1

Exon	Forward 5' to 3'	Reverse 3' to 5'	T _m (°C)	Size (bp)
1	AAATGGGATTTTGGGAATC	GTAAACATGGACGTGGGAGG	TD*	471
2	AAAATTAAATGGTTGATAGAATGTTGC	TCAAGAAGGGATAATGAAGTAACAC	65	583
3	GACATTTCTGTTGCCTTGGG	GCTGTGGCATTCTCATTTTG	65	472
4	TTTTGCTATAATTTGTCATCTTTCAG	TTGTAGGTCAAGGAAGGAAGAGA	60	413
5	TTACTGTTCAGGCATTGGG	TGGAAACCAACCAAACGTAAC	65	430
6	GTGCATGCCACCATGTCT	TGTGTCTGGCCACTCAATAAA	68	398
7	GAATAATGATTTGCAGTATTTC	CAGACAAGGCAACAAAAGTGTC	65	400
8	CATACGGGTAATTTGAAGGGTG	TTTGGGGACAATGTTCTAAGC	65	384
9	CGCCTGGCCCTAGAATAAA	GGCCACATGAGATCAGCTTT	65	491

* Primer sequences used to amplify and sequence RAD51C, with annealing temperature (T_m) and amplicon size (TD – touchdown PCR, indicates that DMSO was added to a final concentration of 10%).

Table 2

Patient	1	2	3	4	5	6	7
Gender	M	M	F	F	F	M	M
Location	Exon 1	Exon 2	Exon 2	Intron 4	Exon 5	Exon 6	Exon 6
Nucleotide change	c.7G>A	c.376G>A	c.376G>A	c.706-2A>G	c.790G>A	c.859A>G	c.859A>G
Protein change	p.G3R	p.126A>T	p.126A>T	Aberrant splicing	p.264G>S	p.287T>A	p.287T>A
Tumor localization	Larynx	Larynx	Oropharynx	Oropharynx	Larynx	Hypopharynx	Larynx
TNM	pT2pN2M0	pT1bN0M0	pT4apN0M0	pT3pN1M1	pT2pN2bM0	pT2N0M0	pT4apN0M0
Additional cancers	Oropharynx (pT3pN0M0)	-	-	-	Bronchial CA (T3N2bM0)	-	-
Nicotine	Y	Y	N	N	N	Y	Y
Alcohol consumption	Y	N	N	N	N	N	Y
HPV	positive	negative	positive	negative	n.t.	negative	positive
Detected in breast cancer	Y	Y	Y	N (ovarian)	Y	Y	Y
Functionally tested	Y	Y	Y	N	Y	Y	Y
Detrimental mutation	N	N	N	Y	Y	Y	Y
Appearance in dbSNP	N	Y	Y	N	Y	Y	Y
dbSNP number	n/a	rs61758784	rs61758784	n/a	rs147241704	rs28363317	rs28363317
Allele count (MAF source: 1000 Genomes)*	n/a	A = 0.001/2	A = 0.001/2	n/a	A = 0.002*	G = 0.006/13	G = 0.006/13

Y = yes; n = no; n.t. = not tested (no specimen available); F = female; M = male; Ex = Exon; MAF = minor allele frequency;

* source = University of Washington/Broad Institute; functional testing as depicted in Meindl et al. [39].